Development and recent progresses of gene therapy for β-thalassemia

β-thalassemias are among the most common inherited monogenic disorders worldwide due to mutations in the β-globin gene that reduce or abolish the production of the β-globin chain resulting in transfusion-dependent chronic anemia. Currently, the only curative treatment is allogeneic hematopoietic stem cells (HSCs) transplantation, but this option is limited by the a vailability of HLA-matched donor. Gene therapy, based on autologous transplantation of genetically corrected HSCs, holds the promise to treat patients lacking a compati ble bone marrow donor. I nit ial attempts of gene transfer have been unsuccessful due to limitations of available vectors to stably transfer a globin gene in HSCs and reach high and regulated expression in the erythroid progeny. With the advent of lentiviral vectors (LVs), based on human immunodeficiency virus, many of the initial limitations have been overcome. Since 2000 when Sadelain and co-workers first demonstrated successful globin gene transfer in murine thalassemia models with improvement of the phenotype using a recombinant β globin/LV, several other groups have developed different vectors encoding either β, γ or mutated globin genes and confirmed these results in both murine models and erythroid progeny derived from patient’s HSCs. In light of these encouraging results, research has recently moved into clinical trials that are ongoing or soon to begin. One participant in an ongoing gene transfer trial for β-thalassemia has achieved clinical benefit with elimination of his transfusi on re quirement. Here , dev elopmen t and recent progress of gene therapy for β-thalassemia is reviewed.

• Publication year

  2014

• Venue

  Thalassemia Reports

• Publication date

  2014-09-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4081/THAL.2014.2925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation.

  2014cited by this paper
• Therapeutic Hemoglobin Levels after Gene Transfer in β-Thalassemia Mice and in Hematopoietic Cells of β-Thalassemia and Sickle Cells Disease Patients

  2012cited by this paper
• Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies.

  2012cited by this paper
• Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients

  2012cited by this paper
• Hematopoietic stem cell engineering at a crossroads.

  2012cited by this paper
• Genetic modifiers of β-thalassemia and clinical severity as assessed by age at first transfusion

  2012cited by this paper
• The Use of Chromatin Insulators to Improve the Expression and Safety of Integrating Gene Transfer Vectors

  2011cited by this paper
• Recent advances in β-thalassemias

  2011cited by this paper
• Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection.

  2011cited by this paper
• The GATA1-HS2 Enhancer Allows Persistent and Position-Independent Expression of a β-globin Transgene

  2011cited by this paper
• Ex vivo gene transfer and correction for cell-based therapies

  2011cited by this paper
• Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in β‐thalassemia

  2010cited by this paper
• Correction of β-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients

  2010cited by this paper
• Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

  2010cited by this paper
• Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience

  2010cited by this paper
• Desensitization to hydroxycarbamide following long‐term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients

  2010cited by this paper
• Hematopoietic stem cell transplantation in thalassemia.

  2010cited by this paper
• The life of patients with thalassemia major

  2010cited by this paper
• The sea urchin sns5 insulator protects retroviral vectors from chromosomal position effects by maintaining active chromatin structure.

  2009cited by this paper
• Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy

  2009cited by this paper
• Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element.

  2009cited by this paper
• Optimized Lentiviral Vector Design Improves Titer and Transgene Expression of Vectors Containing the Chicken β-Globin Locus HS4 Insulator Element.

  2009cited by this paper
• Global epidemiology of haemoglobin disorders and derived service indicators.

  2008cited by this paper
• In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of β-thalassemia

  2008cited by this paper
• Current status of globin gene therapy for the treatment of β‐thalassaemia

  2008cited by this paper
• Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance

  2008cited by this paper
• Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells.

  2007cited by this paper
• Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.

  2007cited by this paper
• Improved Human β-globin Expression from Self-inactivating Lentiviral Vectors Carrying the Chicken Hypersensitive Site-4 (cHS4) Insulator Element.

  2007cited by this paper
• Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.

  2007cited by this paper
• Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element.

  2007cited by this paper
• Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration

  2006cited by this paper
• A Phase I/II Clinical Trial of β‐Globin Gene Therapy for β‐Thalassemia

  2005cited by this paper
• Unrelated Bone Marrow Transplantation for β‐Thalassemia Patients: The Experience of the Italian Bone Marrow Transplant Group

  2005cited by this paper
• Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells.

  2005cited by this paper
• Functional characterization of the sea urchin sns chromatin insulator in erythroid cells.

  2005cited by this paper
• Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences

  2004cited by this paper
• Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector.

  2004cited by this paper
• A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.

  2003cited by this paper
• American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells.

  2003cited by this paper
• The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.

  2003cited by this paper
• Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells

  2002cited by this paper
• The cure of thalassemia by bone marrow transplantation.

  2002cited by this paper
• Development of virus vectors for gene therapy of (cid:1) chain hemoglobinopathies: flanking with a chromatin insulator reduces (cid:2) -globin gene silencing in vivo

  2002cited by this paper
• The beta‐globin locus control region versus gene therapy vectors: a struggle for expression

  2001cited by this paper
• Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin

  2000cited by this paper
• Development of a condensed locus control region cassette and testing in retrovirus vectors for A gamma-globin.

  1998cited by this paper
• HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells.

  1998cited by this paper
• Development of a Self-Inactivating Lentivirus Vector

  1998cited by this paper
• Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors.

  1997cited by this paper
• In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector

  1996cited by this paper
• Thalassemia — a global public health problem

  1996cited by this paper
• Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene.

  1995cited by this paper
• Genotype-phenotype correlations in -thalassemias

  1994cited by this paper
• Genotype-phenotype correlations in beta-thalassemias.

  1994cited by this paper
• Mutagenesis of retroviral vectors transducing human beta‐globin gene and beta‐globin locus control region derivatives results in stable transmission of an active transcriptional structure.

  1994cited by this paper
• The population genetics of the haemoglobinopathies.

  1993cited by this paper
• A human beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells.

  1993cited by this paper
• High-level beta-globin expression after retroviral transfer of locus activation region-containing human beta-globin gene derivatives into murine erythroleukemia cells.

  1990cited by this paper
• A majority of mice show long-term expression of a human beta-globin gene after retrovirus transfer into hematopoietic stem cells

  1989cited by this paper
• Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells.

  1989cited by this paper
• Expression of the human beta-globin gene following retroviral-mediated transfer into multipotential hematopoietic progenitors of mice.

  1988cited by this paper
• Graft-versus-host disease: allo- and autoimmunity after bone marrow transplantation.

  1988cited by this paper
• The Molecular Basis of Blood Diseases

  1988cited by this paper
• Lineage-specific expression of a human β-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells

  1988cited by this paper
• Position-independent, high-level expression of the human beta-globin gene in transgenic mice.

  1987cited by this paper
• Marrow transplantation for thalassaemia.

  1982cited by this paper
• Sounding boards. The potentials of inserting new genetic information.

  1980cited by this paper

• No citing papers are available for this paper.